Logo Image
Opinion|Videos|September 27, 2024

Established Multidisciplinary Therapies for SCLC

Panelists discuss how conventional therapies for extensive-stage and limited-stage small cell lung cancer (SCLC) have evolved, including the role of chemoradiotherapy (CRT) and its various schedules, while exploring unmet needs in extensive-stage settings and the potential for combining immunotherapies with CRT to improve treatment outcomes.

Episodes in this series
  • What are the conventional therapies that have been used to treat extensive-stage (small cell lung cancer) SCLC and what has their data shown?

a. What are the current unmet needs in extensive-stage settings?

  • What are the therapies used for limited-stage SCLC and what is the role of chemoradiotherapy (CRT), and what has the data shown?

a. What are the differences between the schedules of CRT, eg, daily/twice daily/sequential?

  • Do you see opportunities in building upon CRT as a standard of care by including systemic therapies, such as immunotherapies, in combination?